Please ensure Javascript is enabled for purposes of website accessibility

The 3 Greatest Risks Pfizer Faces

By Keith Speights – Apr 14, 2019 at 7:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here's what could get in the way of the big pharma company's future success.

Pfizer (PFE 0.73%) shareholders have plenty of reasons to be optimistic. Shares of the big drugmaker are up 15% over the last 12 months, well above the return of the S&P 500 index. Pfizer's dividend yield of nearly 3.4% looks also should bring smiles to investors' faces. And the company arguably has its strongest pipeline in years.

But the future won't necessarily be a cakewalk for Pfizer. There are several potential obstacles that could cause the big pharma company to stumble. Here are the three greatest risks that Pfizer faces.

Man with magnifying glass held up to wooden blocks spelling "risk"

Image source; Getty Images.

1. Major healthcare system changes

Perhaps the most significant of all the risks for Pfizer is the possibility of major upheaval in the U.S. healthcare system. Politicians in both parties have made drugmakers the targets of their wrath. Lawmakers are especially focusing on drug price increases they consider to be unwarranted.

It's not surprising then that Pfizer attracted criticism when it announced price increases for 41 of its drugs effective Jan. 15. Investment firm Leerink conducted a study that found Pfizer was one of the major pharmaceutical companies most dependent on drug price increases to spur revenue growth. That could be problematic if big changes are made that hamper Pfizer's ability to boost prices for its drugs.

Then there's the potential for single-payer healthcare in the United States. The Medicare-for-All proposal by Sen. Bernie Sanders would radically change the dynamics for many companies in the healthcare sector.  Drugmakers would negotiate only with the federal government on drug prices. That would almost certainly mean Pfizer wouldn't be able to charge as much for its drugs.

2. Slowing sales for top drugs

Sales for Pfizer's top drugs could slip even if there aren't huge changes in the U.S. healthcare system. Actually, you can bet that sales for several of the company's blockbuster drugs will fall. Lyrica, which made $4.6 billion in 2018, loses patent exclusivity this year. Enbrel already faces competition from biosimilars in Europes. 

Competition could present problems for other Pfizer drugs as well. The company is counting on breast cancer drug Ibrance to be a growth driver for years to come. But Ibrance faces a big challenger with Eli Lilly's Verzenio. Several drugmakers also have promising drugs that could be on the market within the next few years.

Pfizer's biggest-selling product right now is pneumococcal vaccine Prevnar 13. But Merck aims to take Prevnar 13 head-on with its V114 that's currently in late-stage clinical studies and could potentially win FDA approval next year. 

3. Significant pipeline setbacks

Every biopharmaceutical company faces the risks of pipeline failures. Pfizer is no exception.

If you look at Pfizer's pipeline, you'll find that six of its late-stage programs are evaluating Bavencio in treating various types of cancer. But Pfizer and its partner, Merck KGaA, which is based in Germany and is a different company from the U.S.-based Merck, already announced one late-stage failure for the immunotherapy in treating lung cancer. That doesn't mean other phase 3 studies will flop, but it underscores the risk Pfizer faces.

Pipeline setbacks can also come in the form of an FDA decision against approval for a drug. Pfizer had such an experience a year ago, when the FDA rejected approval of the company's biosimilar to Herceptin. While the company subsequently obtained approval for the biosimilar last month, the year-long delay hurt. 

Putting the risks in perspective

Investors shouldn't ignore the risks Pfizer faces. They're real, and they could potentially cause the big pharma stock to underperform over the next few years. At the same time, though, these risks should also be put in perspective.

Pfizer has successfully navigated major changes to the U.S. healthcare system before. Even though the company raised prices on 41 of its drugs this year, Pfizer has adjusted to the new political dynamics and expects the net impact on revenue to be minimal. Also, the implementation of a single-payer healthcare system in the U.S. faces an uphill battle.

And while Pfizer could be hurt by competition for its top drugs or pipeline setbacks for key candidates, the company's product lineup and pipeline are well diversified. No product currently generates more than 11% of total revenue. Pfizer's pipeline includes around 100 programs, 26 of which are in late-stage development.

Investing always comes with risks. But there's no reason for Pfizer's risks to diminish investors' optimism about the company's long-term prospects.

Keith Speights owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Stock Quote
Pfizer
PFE
$49.57 (0.73%) $0.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.